

17 Jul 2018 | **News**

QUOTED. July 17, 2018. David Brunel.

by

Biodesix Inc. is acquiring Integrated Diagnostics Inc. for both its flagship XL2 lung-cancer test and to upgrade its ability to develop new pharma companion diagnostics. See what Biodesix CEO David Brunel said about it [here](#).

"That is perfect for us, because our primary call point is the pulmonologist and this is one of the big questions they're asking us to help address. It was just a natural fit for our [customer] call-point and with our strategy of trying to be a comprehensive provider of all the necessary tools to help physicians diagnose and treat this disease." –David Brunel, CEO, Biodesix Inc.

- Find out more: [*Biodesix Cites 'Natural Fit' Of Acquired Integrated Diagnostics Lung Cancer Test*](#)

[*Click here*](#) for a free trial of *Medtech Insight*